Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner
Open Access
- 10 April 2017
- journal article
- research article
- Published by Springer Nature in Oncogenesis
- Vol. 6 (4) , e314
Abstract
Chemotherapy and radiation, the two most common cancer therapies, exert their anticancer effects by causing damage to cellular DNA. However, systemic treatment damages DNA not only in cancer, but also in healthy cells, resulting in the progression of serious side effects and limiting efficacy of the treatment. Interestingly, in response to DNA damage, p53 seems to play an opposite role in normal and in the majority of cancer cells—wild-type p53 mediates apoptosis in healthy tissues, attributing to the side effects, whereas mutant p53 often is responsible for acquired cancer resistance to the treatment. Here, we show that leucine zipper-containing ARF-binding protein (LZAP) binds and stabilizes p53. LZAP depletion eliminates p53 protein independently of its mutation status, subsequently protecting wild-type p53 cells from DNA damage-induced cell death, while rendering cells expressing mutant p53 more sensitive to the treatment. In human non-small-cell lung cancer, LZAP levels correlated with p53 levels, suggesting that loss of LZAP may represent a novel mechanism of p53 inactivation in human cancer. Our studies establish LZAP as a p53 regulator and p53-dependent determinative of cell fate in response to DNA damaging treatment.Keywords
This publication has 72 references indexed in Scilit:
- Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 WorkshopCell Death & Differentiation, 2011
- Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agentsProceedings of the National Academy of Sciences, 2011
- Tumor suppressor Lzap regulates cell cycle progression, doming, and zebrafish epibolyDevelopmental Dynamics, 2011
- A Novel C53/LZAP-interacting Protein Regulates Stability of C53/LZAP and DDRGK Domain-containing Protein 1 (DDRGK1) and Modulates NF-κB SignalingJournal of Biological Chemistry, 2010
- The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich elementProceedings of the National Academy of Sciences, 2009
- Tumor suppressor protein C53 antagonizes checkpoint kinases to promote cyclin-dependent kinase 1 activationCell Research, 2009
- Wrap53, a Natural p53 Antisense Transcript Required for p53 Induction upon DNA DamageMolecular Cell, 2009
- TP53Mutations and Survival in Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2007
- The role of p53 in determining sensitivity to radiotherapyNature Reviews Cancer, 2003
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002